Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | VP, Corporate Controller | June 13, 2022 | June 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,447 |
Reported balance
After 2022-06-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-13 · Sale · Disposed 42 · Balance 4,447 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This number includes unvested RSUs previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This number includes unvested RSUs previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2019 Filed Aug 12, 2019 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 475 | $93.52 | $44,422.00 |
DisclosureSEC source: 0001127602-19-026402 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 94 | $110.58 | $10,394.52 |
DisclosureSEC source: 0000899243-19-017191 · doc4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,789 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 39 | $109.37 | $4,265.43 |
DisclosureSEC source: 0001127602-19-021564 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,883 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 192 | $104.38 | $20,040.96 |
DisclosureSEC source: 0001127602-19-021464 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,922 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 78 | $103.38 | $8,063.64 |
DisclosureSEC source: 0001127602-19-021240 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,114 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,107 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-19-021240 · form4.xml · derivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213 Underlying: Common Stock · 1,107 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,107 | $103.25 | $114,297.75 |
DisclosureSEC source: 0001127602-19-021240 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,192 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,107 | $41.64 | $46,095.48 |
DisclosureSEC source: 0001127602-19-021240 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:43 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 2,003 | $0.00 Strike: $98.03 | $0.00 |
DisclosureSEC source: 0001127602-19-018752 · form4.xml · derivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,003 Underlying: Common Stock · 2,003 shares Expires 2026-05-14 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:43 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018752 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,192 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 389 | $88.99 | $34,617.11 |
DisclosureSEC source: 0001127602-19-015179 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,619 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,607 | $0.00 Strike: $34.42 | $0.00 |
DisclosureSEC source: 0001127602-19-015179 · form4.xml · derivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,607 Underlying: Common Stock · 2,607 shares Expires 2023-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 210 | $88.31 | $18,545.10 |
DisclosureSEC source: 0001127602-19-015179 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,008 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,607 | $88.93 | $231,840.51 |
DisclosureSEC source: 0001127602-19-015179 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,218 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:54 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,607 | $34.42 | $89,732.94 |
DisclosureSEC source: 0001127602-19-015179 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:07 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,457 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0001127602-18-036101 · form4.xml · derivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913 Underlying: Common Stock · 1,457 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:07 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,693 | $102.91 | $174,226.63 |
DisclosureSEC source: 0001127602-18-036101 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,218 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:07 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,457 | $34.21 | $49,843.97 |
DisclosureSEC source: 0001127602-18-036101 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 102 | $101.69 | $10,372.38 |
DisclosureSEC source: 0001127602-18-031285 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,454 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,903 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020841 · form4.xml · derivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,903 Underlying: Common Stock · 1,903 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020841 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,556 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 578 | $92.90 | $53,696.20 |
DisclosureSEC source: 0001127602-18-020725 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 F1 · shares: Sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 81 | $92.73 | $7,511.13 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 5 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F2 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,106 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · derivative · entry 7 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,320 Underlying: Common Stock · 1,106 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,607 | $0.00 Strike: $34.42 | $0.00 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · derivative · entry 6 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,214 Underlying: Common Stock · 2,607 shares Expires 2023-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,106 | $95.14 | $105,224.84 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,681 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,607 | $95.14 | $248,029.98 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,787 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,106 | $41.64 | $46,053.84 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,607 | $34.42 | $89,732.94 |
DisclosureSEC source: 0001127602-18-020476 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 22:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 210 | $72.19 | $15,159.90 |
DisclosureSEC source: 0001127602-18-014343 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,681 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,456 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · derivative · entry 14 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Underlying: Common Stock · 1,456 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,607 | $0.00 Strike: $34.42 | $0.00 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · derivative · entry 13 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,821 Underlying: Common Stock · 2,607 shares Expires 2023-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 68 | $54.89 | $3,732.25 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 10 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,199 Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 560 | $54.84 | $30,710.96 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 9 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,267 Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 956 | $54.96 | $52,538.89 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 8 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,827 Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $54.94 | $10,988.00 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 7 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,783 Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $54.92 | $16,476.30 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 6 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,983 Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,607 | $54.95 | $143,241.62 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 5 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,283 Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,456 | $34.21 | $49,809.76 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 4 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,607 | $34.42 | $89,732.94 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 3 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2017 Filed Apr 10, 2018 22:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 111 | $46.76 | $5,190.36 |
DisclosureSEC source: 0001127602-18-014343 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,891 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 19, 2017 Filed Apr 10, 2018 22:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 197 | $40.39 | $7,956.83 |
DisclosureSEC source: 0001127602-18-014343 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 06, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,426 | $41.64 Strike: $41.64 | $184,298.64 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · derivative · entry 12 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,426 Underlying: Common Stock · 4,426 shares Expires 2024-06-06 F2 · shares: Non-qualified stock option grant providing a right to buy shares of common stock exercisable in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 06, 2017 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,827 F1 · shares: Restricted Stock Units which vest 25% per year over 4 years following the grant date. Read SEC document |
| October 25, 2016 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,826 | $34.21 Strike: $34.21 | $199,307.46 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · derivative · entry 11 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,826 Underlying: Common Stock · 5,826 shares Expires 2023-10-25 F2 · shares: Non-qualified stock option grant providing a right to buy shares of common stock exercisable in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Nov 15, 2017 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-032257 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,747 F1 · shares: Restricted Stock Units which vest 25% per year over 4 years following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.